Conference Call with Natco Pharma Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Natco Pharma announced Q4FY24 & FY24 results: Q4FY24: Total Revenue stood at Rs 11,103 million Pharma Export Formulations at Rs 9,549 million Consolidated Total Revenue for FY24 stood at Rs 41,269 million Earnings Before Interest Tax Depreciation and Amortization stood at Rs 5,393 million for Q4FY24 and Rs 18,795 million for FY24 EBITDA Margin for Q4FY24 & FY24 was at 48.6% and 45.5% respectively Profit Before Tax for Q4FY24 at Rs 4,776 million and Rs 16,735 million for FY24 Basic and Diluted EPS for FY24 is Rs 77.34 per share Profit after tax for Q4FY24 was at Rs 3,863 million Net Profit for FY24 was at Rs 13,883 million EBITDA and EBITDA Margin includes other income Investment of USD 2 million in Cellogen Therapeutics Private Ltd., with R&D; programs involving Cell and Gene Therapy Solutions Result PDF
Conference Call with Natco Pharma Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.